Agensys Overview
- Year Founded
-
1996
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$537M
- Investors
-
1
Agensys General Information
Description
Developer of therapeutic human monoclonal antibodies and antibody-drug conjugates for the treatment of cancer. The company develops products to treat various tumors, as well as prostate, kidney, bladder, lung, and colon cancers, thereby enabling patients with treatment for cancers.
Contact Information
Website
www.agensys.comCorporate Office
- 2225 Colorado Avenue
- Santa Monica, CA 90404
- United States
Corporate Office
- 2225 Colorado Avenue
- Santa Monica, CA 90404
- United States
Agensys Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 18-Dec-2007 | $537M | Completed | Clinical Trials - Phase 2 | ||
| 5. Later Stage VC (Series D) | 12-Jul-2007 | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC (Series C) | 05-Mar-2002 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC (Series B) | 01-Nov-1999 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A) | 10-Nov-1997 | $8M | $8M | Completed | Product Development | |
| 1. University Spin-Out | 01-Jan-1996 | Completed | Startup |
Agensys Comparisons
Industry
Financing
Details
Agensys Competitors (20)
One of Agensys’s 20 competitors is Exelixis, a Formerly VC-backed company based in Alameda, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Exelixis | Formerly VC-backed | Alameda, CA | ||||
| Seagen | Formerly VC-backed | Bothell, WA | ||||
| Sutro Biopharma | Formerly VC-backed | South San Francisco, CA | ||||
| Amgen | Formerly PE-Backed | Thousand Oaks, CA | ||||
| Helsinn Healthcare | Corporation | Lugano, Switzerland |
Agensys Patents
Agensys Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024344898-A1 | Treating locally advanced or metastatic urothelial cancer with anti-191p4d12 antibody drug conjugates in combination with pembrolizumab | Pending | 21-Sep-2023 | ||
| EP-4780498-A1 | Treating locally advanced or metastatic urothelial cancer with anti-191p4d12 antibody drug conjugates in combination with pembrolizumab | Pending | 21-Sep-2023 | ||
| WO-2025064741-A1 | Treating locally advanced or metastatic urothelial cancer with anti-191p4d12 antibody drug conjugates in combination with pembrolizumab | Inactive | 21-Sep-2023 | ||
| WO-2024129554-A3 | Combination therapy | Inactive | 16-Dec-2022 | ||
| WO-2024129552-A2 | Combination therapy of a pd-1 antagonist, a lag3 antagonist and an antibody drug conjugate that binds 191p4d12 protein for treating patients with cancer | Inactive | 16-Dec-2022 | C07K16/2803 |
Agensys Former Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alta Partners | Venture Capital | Minority | ||
| Bear Stearns Health InnoVentures Management | Venture Capital | Minority | ||
| Bellco Capital | PE/Buyout | Minority | ||
| Carnegie Investment Counsel | Asset Manager | Minority | ||
| Duquesne Light | Corporation | Minority |
Agensys Investments (1)
Agensys’s most recent deal was a Corporate Asset Purchase with Agensys (160,000 square foot site). The deal was made on 11-Jan-2011.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Agensys (160,000 square foot site) | 11-Jan-2011 | Corporate Asset Purchase | Buildings and Property |
Agensys FAQs
-
When was Agensys founded?
Agensys was founded in 1996.
-
Where is Agensys headquartered?
Agensys is headquartered in Santa Monica, CA.
-
What industry is Agensys in?
Agensys’s primary industry is Drug Delivery.
-
Is Agensys a private or public company?
Agensys is a Private company.
-
What is the current valuation of Agensys?
The current valuation of Agensys is .
-
What is Agensys’s current revenue?
The current revenue for Agensys is .
-
How much funding has Agensys raised over time?
Agensys has raised $103M.
-
Who are Agensys’s investors?
Alta Partners, Bear Stearns Health InnoVentures Management, Bellco Capital, Carnegie Investment Counsel, and Duquesne Light are 5 of 15 investors who have invested in Agensys.
-
Who are Agensys’s competitors?
Exelixis, Seagen, Sutro Biopharma, Amgen, and Helsinn Healthcare are some of the 20 competitors of Agensys.
-
When was Agensys acquired?
Agensys was acquired on 18-Dec-2007.
-
Who acquired Agensys?
Agensys was acquired by Astellas Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process